Goadsby Peter J
Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, London, UK.
Drugs. 2005;65(18):2557-67. doi: 10.2165/00003495-200565180-00002.
Calcitonin gene-related peptide (CGRP) is a potent neuromodulator that is expressed in the trigeminovascular system and is released into the cranial circulation in various primary headaches. CGRP is released in migraine, cluster headache and paroxysmal hemicrania. The blockade of its release is associated with the successful treatment of acute migraine and cluster headache. CGRP receptor blockade has recently been shown to be an effective acute anti-migraine strategy and is non-vasoconstricting in terms of the mechanism of action. The prospect of a non-vasoconstricting therapy for acute migraine offers a real opportunity to patients, and perhaps more importantly, provides a therapeutic rationale to reinforce migraine as a neurological disorder.
降钙素基因相关肽（CGRP）是一种强效神经调节剂，在三叉神经血管系统中表达，并在各种原发性头痛中释放到颅内循环中。CGRP在偏头痛、丛集性头痛和发作性偏侧头痛中释放。阻断其释放与急性偏头痛和丛集性头痛的成功治疗相关。最近研究表明，CGRP受体阻断是一种有效的急性抗偏头痛策略，就作用机制而言不具有血管收缩作用。急性偏头痛的非血管收缩治疗前景为患者提供了真正的机会，也许更重要的是，为将偏头痛强化为一种神经系统疾病提供了治疗依据。
